Perspectivas de tratamiento con GH en el adulto con síndrome de Prader-Willi

Prader-Willi syndrome (PWS) is a genetic disorder. In adults it is characterized by abnormal body composition, excessive eating and progressive obesity with increased cardiovascular morbidity and mortality. Scientific evidence shows that there is partial growth hormone (GH) deficiency in PWS. Therefore, these patients could be expected to show the same clinical manifestations as those observed in adults with GH deficiency syndrome (GHDS) and to obtain the same benefit from hormone replacement therapy as GHDS patients. A recent study has demonstrated that GH treatment for 12 months in adults with PWS improved body composition and psychological status without producing pronounced adverse effects on glucose and lipid metabolism. However, larger, prospective studies with suitable control groups are required to confirm these results before GH replacement is used as therapy in adults with PWS.